Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04602481Recruiting

Living With Primary Ciliary Dyskinesia (Living With PCD)

Role: collaborator

NCT06120855Not ApplicableActive Not Recruiting

Study on Regulated Cannabis Sales in Pharmacies

Role: collaborator

NCT07180615Phase 4Not Yet Recruiting

Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery

Role: lead

NCT06540911Not ApplicableCompleted

Personalized Physical Back Training Program to Improve Physical Functioning in People with Non-specific Low Back Pain: a Feasibility Study

Role: lead

NCT05217212Unknown

Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?

Role: collaborator

NCT04306172Completed

Validation of EPIC's Readmission Risk Model, the LACE+ Index and SQLape as Predictors of Unplanned Hospital Readmissions

Role: collaborator

NCT02826473Not ApplicableTerminated

Focused Cognitive Testing in Inpatients

Role: collaborator

All 7 trials loaded